- Main
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120
- Chirenje, ZM;
- Laher, F;
- Dintwe, O;
- Muyoyeta, M;
- Decamp, AC;
- He, Z;
- Grunenberg, N;
- Laher Omar, F;
- Seaton, KE;
- Polakowski, L;
- Woodward Davis, AS;
- Maganga, L;
- Baden, LR;
- Mayer, K;
- Kalams, S;
- Keefer, M;
- Edupuganti, S;
- Rodriguez, B;
- Frank, I;
- Scott, H;
- Stranix-Chibanda, L;
- Gurunathan, S;
- Koutsoukos, M;
- Van Der Meeren, O;
- Diazgranados, CA;
- Paez, C;
- Andersen-Nissen, E;
- Kublin, J;
- Corey, L;
- Ferrari, G;
- Tomaras, G;
- McElrath, MJ
Published Web Location
https://doi.org/10.1093/infdis/jiad434Abstract
Background: HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled human immunodeficiency virus (HIV) vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent subtype C gp120 Env protein at 2 dose levels in healthy HIV-uninfected adults. Methods: Participants received ALVAC-HIV (vCP2438) alone or placebo at months 0 and 1. At months 3 and 6, participants received either placebo, ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with MF59 or AS01B, or ALVAC-HIV (vCP2438) with 40 μg of bivalent subtype C gp120 adjuvanted with AS01B. Primary outcomes were safety and immune responses. Results: We enrolled 160 participants, 55% women, 18-40 years old (median age 24 years) of whom 150 received vaccine and 10 placebo. Vaccines were generally safe and well tolerated. At months 6.5 and 12, CD4+ T-cell response rates and magnitudes were higher in the AS01B-adjuvanted groups than in the MF59-adjuvanted group. At month 12, HIV-specific Env-gp120 binding antibody response magnitudes in the 40 μg gp120/AS01B group were higher than in either of the 200 μg gp120 groups. Conclusions: The 40 μg dose gp120/AS01B regimen elicited the highest CD4+ T-cell and binding antibody responses.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.